2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11D.04 A Phase 1/2 Study of REGN7075 (EGFRÃ-CD28) Combined with Cemiplimab (anti-PD-1) In NSCLC: Trial in Progress Update

P4.11D.04 A Phase 1/2 Study of REGN7075 (EGFRÃ-CD28) Combined with Cemiplimab (anti-PD-1) In NSCLC: Trial in Progress Update

Back to course

Pdf Summary

A clinical study presented at the World Conference on Lung Cancer in 2024 details the investigation of a novel cancer treatment involving the combination of REGN7075, an EGFRCD28 bispecific antibody, with cemiplimab, an anti-PD-1 agent, in patients with advanced solid tumors such as non-small cell lung cancer (NSCLC). This study, registered as NCT04626635, aims to address the challenge of poor responses to existing immunotherapies in some cancer types.<br /><br />The study consists of two phases: a dose escalation phase to determine the safety and tolerability of REGN7075, both alone and in combination with cemiplimab, and a dose expansion phase to assess its preliminary efficacy across various tumor types, specifically EGFR-expressing cancers like NSCLC. The primary objectives include evaluating safety and tolerability and assessing the response rate of combination therapy measured by objective response rate and disease control rate. Secondary and exploratory goals involve understanding pharmacokinetics, immunogenicity, and biomarker responses.<br /><br />REGN7075 is a first-in-class antibody that simultaneously binds to EGFR on tumors and CD28 on T cells, potentially enhancing T-cell-mediated antitumor activity. Combined with cemiplimab, which inhibits a major tumor suppressive pathway, this approach is expected to leverage natural antitumor immunity. More than 100 patients have been enrolled in the dose escalation phase, with plans to extend to over 500 patients in the dose expansion phase, including those with non-curative NSCLC.<br /><br />The study is funded by Regeneron Pharmaceuticals and emphasizes the pressing need for innovative treatments in oncology, particularly for tumors with resistance to conventional immunotherapies. Results from this trial could provide critical insights into the therapeutic potential of REGN7075 when used alongside cemiplimab in cancer treatment.

Asset Subtitle

Melissa Johnson

Meta Tag

Speaker Melissa Johnson

Topic Metastatic NSCLC – Immunotherapy

Keywords

World Conference on Lung Cancer 2024

REGN7075

EGFRCD28 bispecific antibody

cemiplimab

anti-PD-1 agent

non-small cell lung cancer

NCT04626635

immunotherapy

Regeneron Pharmaceuticals

oncology